FDA proposes adding suffixes to distinguish biosimilar drug names

WASHINGTON, Aug 27 (Reuters) - Cheaper versions of biologic drugs would be identified by a suffix to distinguish them from their more expensive, branded counterparts under draft guidance issued on Thursday by the U.S. Food and Drug Administration.